Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Camurus AB ( (SE:CAMX) ) just unveiled an announcement.
Camurus AB announced an increase in the number of shares and votes following the exercise of employee stock options and the issuance of series C shares to fulfill commitments under its long-term incentive program. This move, which resulted in an increase of 781,566 shares and votes, reflects the company’s ongoing efforts to incentivize its employees and align with its strategic growth objectives.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus is an international biopharmaceutical company focused on developing and commercializing long-acting medicines for severe and chronic diseases. Utilizing its proprietary FluidCrystal technology and extensive R&D expertise, the company targets treatments for dependence, pain, cancer, and endocrine diseases. Camurus operates across Europe, the US, and Australia, with headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm under the ticker CAMX.
YTD Price Performance: 7.43%
Average Trading Volume: 196,853
Current Market Cap: SEK36.22B
Find detailed analytics on CAMX stock on TipRanks’ Stock Analysis page.